Skip to main content

Enveric Biosciences, Inc.

ENVB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0000890821

No open-market purchases or sales by Enveric Biosciences, Inc. insiders were filed in the last 90 days; 24 institutions reported holding it in 13F filings for Q2 2026, worth $736.8K in total; no superinvestor holds it.

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +13 vs. previous quarter
24
13F valueReported value at the end of Q2 2026
$736.8K
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding ENVB, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding ENVB at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by Enveric Biosciences, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 19, 2023 (view filing)Sep 154 daysPasqualone FrankDirectorPPurchase+1.00K$2.14+$2.14KNew position1.00K after

Top 10 13F holders, Q2 2026

The largest institutional positions in Enveric Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 24 holders
Institutions holding ENVB in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Sio Capital Management, LLC180,000$248.4K0.04%+180,000New
Ikarian Capital, LLC100,002$138.0K0.02%+100,002New
AdvisorShares Investments LLC35,417$48.9K0.01%+18,443+108.7%Added
Renaissance Technologies LLC32,058$44.2K0.00%+32,058New
Armistice Capital, LLC32,000$44.2K0.00%+32,000New
Boothbay Fund Management, LLC30,142$41.6K0.00%+30,142New
XTX Topco Ltd18,990$26.2K0.00%+18,990New
StoneX Group Inc.11,814$21.9K0.00%+11,814New
HRT Financial LP15,458$21.0K0.00%+15,458New
Vanguard Capital Management LLC14,912$20.6K0.00%+14,912New